ClinicalTrials.gg
Status unknownNCT03232710Updated Jul 28, 2017

Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition

An interventional study of Bosiqing and abilify in Bioequivalence, sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-28.

Sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd. · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
All
01

Study summary

To compare the rate and extent of absorption of Aripiprazole Orally disintegrating tablets 10 mg of Chengdu Kanghong Pharmaceutical Group Co.,Ltd, China and ABILIFY (Aripiprazole) 10 mg orodispersible tablets of Otsuka Pharmaceutical Europe Ltd. in healthy, adult, human subjects under fasting/fed condition as well as to monitor the safety and tolerability of subjects.

02

Conditions studied

  • Bioequivalence
03

In context

Lead sponsor

Chengdu Kanghong Pharmaceutical Group Co., Ltd. is the lead sponsor of 11 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects willing to adhere to the protocol requirements and to provide written .
  2. Subjects aged between 45 and 65 years,healthy male and non-pregnant, non breast feeding female.
  3. Subjects' weight within clinically acceptable normal range according to normal values for (19.00 to 26.00 kg/m2) with minimum of 50 kg weight for male, and minimum of 45 kg weight for female.
  4. No medical history of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.

Exclusion criteria

Exclusion Criteria:

  • 1)Subjects with family history of muscular dystonia or the subject has had the drug source dystonia.

    2)Subject with history of a asthma. 3)Subject with any (acute or chronic) history of mental illness or have family history of mental illness.

    4)Subject have alzheimer's or alzheimer's disease. 5)Subject was hospitalized within 60 days prior to the first dose of the study drug 6)Subject smoking more than five cigarettes within 1 month prior to the first dose study drug.

    7)History or presence of significant easy bruising or bleeding 8)History or presence of drug abuse. 9)History of allergic reactions. 10)History or presence of taking psychotropic drugs。 11)Subjects having positive urine screen for drugs of abuse including Methamphetamine, MDMA, ketamine, morphine, heroin.

    12)Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 3 weeks prior to Period 01 dosing.

    13)Consumption of hypericum perforatum containing products and grapefruit or grapefruit juice from 72 hours prior admission to 3 days after trail end.

    14)Subject involved other clinical trials of drugs within 3 months prior to period 01 dosing.

    15)Subject with abnormal laboratory tests and diagnosed by physicians as 17)Abnormal vital signs test for any one or more:

Abnormal blood pressure:

  • Systolic pressure is lower than 80mmHg and/or diastolic pressure down to 40mmHg in sitting position.
  • Systolic pressure is higher than 140mmHg and/or diastolic pressure higher than 90mmHg in sitting position.

Abnormal cardiac rate:

  • cardiac rate lower than 50
  • cardiac rate higher than 50 18)Blood alcohol test values≥10mg/dL 19)Volunteer who have donated blood components within 2 weeks prior to the first dose or donated blood (more than 200 ml within 4 weeks; more than 400 ml within 60 days) prior to the first dose; Volunteer who plan to donate blood during the study or 4 weeks after study; Volunteer who lost blood (more than 50ml within 7days or more than 400ml within 30 days) for surgery.

    20)Subjects not willing to follow approved methods for the duration of the study 21)ubjects having positive Serum β-hCG test. 22)Subjects plan to donate sperm during study period or 30 days after study 23)Hamilton depression Rating Scale ( 17 ) score above 7 points. 24)History of blood phobia. Subjects whom the investigator deems necessary to exclude.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    pilot study group

    Drug: abilify

  • Experimental
    group 1 (under fasting condition)

    Drug: Bosiqing · Drug: abilify

  • Experimental
    group 2 (under fasting condition)

    Drug: Bosiqing · Drug: abilify

  • Experimental
    group 3 (under fed condition)

    Drug: Bosiqing · Drug: abilify

  • Experimental
    group 4 (under fed condition)

    Drug: Bosiqing · Drug: abilify

Interventions

  • DrugBosiqing

    Aripiprazole Orally disintegrating tablets 10mg

  • Aripiprazol orodispersible tablets 10mg

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter: Cmax

    Bioequivalence based on Peak Plasma Concentration (Cmax) under fasting and fed condition

    Time frame: day 54

  2. Pharmacokinetic parameter: AUC

    Bioequivalence based on Area under the plasma concentration versus time curves (AUC) under fasting and fed condition

    Time frame: day 54

Secondary outcomes

  1. Adverse Events

    To observe the type, incidence and severity of adverse events in the study.

    Time frame: up to day 54

07

Study locations

1 of 1 sites recruiting
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2017 (actual). Primary completion is estimated for Apr 2018, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2017
First posted
Jul 28, 2017
StartActual
Jun 26, 2017
Primary completionEst.
Apr 30, 2018
CompletionEst.
Jun 30, 2018
Last update
Jul 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03232710
Responsible party
Sponsor
First posted
Jul 28, 2017
Start date
Jun 26, 2017
Primary completion
Apr 30, 2018 (estimated)
Completion
Jun 30, 2018 (estimated)
Last update
Jul 28, 2017

Study contacts

Xiang Jin
Contact
11679295@qq.com
+83-13880932568

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion